{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T10:56:11Z","timestamp":1786791371439,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007231","name":"Cornell University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003668","name":"Korea Institute of Planning and Evaluation for Technology in Food Agriculture Forestry and Fisheries","doi-asserted-by":"publisher","award":["RS-2025-02304897"],"award-info":[{"award-number":["RS-2025-02304897"]}],"id":[{"id":"10.13039\/501100003668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007567","name":"City University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["KK2432-10"],"award-info":[{"award-number":["KK2432-10"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lfs.2026.124357","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:43:40Z","timestamp":1774939420000},"page":"124357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation"],"prefix":"10.1016","volume":"394","author":[{"given":"Weiyi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Chae","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhye","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Soo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yong","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Young","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.lfs.2026.124357_bb0005","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41392-022-00997-x","article-title":"SARS-CoV-2 omicron variant: recent progress and future perspectives","volume":"7","author":"Fan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.lfs.2026.124357_bb0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3181\/0903-MR-94","article-title":"Coronavirus diversity, phylogeny and interspecies jumping","volume":"234","author":"Woo","year":"2009","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.lfs.2026.124357_bb0020","first-page":"7","article-title":"The coronaviruses of animals and birds: their zoonosis, vaccines, and models for SARS-CoV and SARS-CoV2","author":"Alluwaimi","year":"2020","journal-title":"Front Vet Sci."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0025","article-title":"Overview of lethal human coronaviruses","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct Tar."},{"key":"10.1016\/j.lfs.2026.124357_bb0030","article-title":"Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae)","volume":"21501-X","author":"L","year":"2021","journal-title":"Encyclopedia of Virology"},{"issue":"21","key":"10.1016\/j.lfs.2026.124357_bb0035","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"P Natl Acad Sci USA."},{"issue":"9","key":"10.1016\/j.lfs.2026.124357_bb0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2026.124357_bb0045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181(4):894-+","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbrc.2004.04.141","article-title":"Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors","volume":"319","author":"Zhu","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.lfs.2026.124357_bb0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0065","article-title":"Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Tar."},{"issue":"7","key":"10.1016\/j.lfs.2026.124357_bb0070","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrmicro3475","article-title":"Broad-spectrum antivirals against viral fusion","volume":"13","author":"Vigant","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"10.1016\/j.lfs.2026.124357_bb0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-virology-022221-063725","article-title":"Small-molecule inhibition of viral fusion glycoproteins","volume":"8","author":"Liu","year":"2021","journal-title":"Annual Review of Virology"},{"issue":"17","key":"10.1016\/j.lfs.2026.124357_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710067","article-title":"Targeting the SARS-CoV-2 HR1 with small molecules as inhibitors of the fusion process","volume":"23","author":"Gentile","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.lfs.2026.124357_bb0085","doi-asserted-by":"crossref","first-page":"2000224","DOI":"10.1002\/adtp.202000224","article-title":"Drug repurposing of Itraconazole and estradiol benzoate against COVID-19 by blocking SARS-CoV-2 spike protein-mediated membrane fusion","volume":"4","author":"Yang","year":"2021","journal-title":"Adv Ther (Weinh)."},{"issue":"4","key":"10.1016\/j.lfs.2026.124357_bb0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.lfs.2026.124357_bb0095","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s11427-023-2410-5","article-title":"A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery","volume":"66","author":"Wu","year":"2023","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med. Public Health Prep."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0105","doi-asserted-by":"crossref","first-page":"15771","DOI":"10.1038\/s41598-017-15467-6","article-title":"Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis","volume":"7","author":"Shiryaev","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.lfs.2026.124357_bb0110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.lfs.2026.124357_bb0115","first-page":"26","article-title":"Remdesivir receives emergency use authorization for severely ill patients with COVID-19","volume":"120","author":"Aschenbrenner","year":"2020","journal-title":"Am. J. Nurs."},{"issue":"2","key":"10.1016\/j.lfs.2026.124357_bb0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s43441-020-00212-5","article-title":"Emergency use authorization for Remdesivir and its potential implications","volume":"55","author":"Ochoa Chaar","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.lfs.2026.124357_bb0125","series-title":"Emerging Variants of SARS-CoV-2 and Novel Therapeutics against Coronavirus (COVID-19)","author":"Aleem","year":"2024"},{"issue":"5","key":"10.1016\/j.lfs.2026.124357_bb0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41564-023-01356-4","article-title":"Therapeutics for COVID-19","volume":"8","author":"Toussi","year":"2023","journal-title":"Nat. Microbiol."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13543784.2022.2030310","article-title":"Monoclonal antibody therapies in the management of SARS-CoV-2 infection","volume":"31","author":"Miguez-Rey","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.lfs.2026.124357_bb0140","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.lfs.2026.124357_bb0145","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613(7944):558-+","author":"Iketani","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lfs.2026.124357_bb0150","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/cid\/ciac769","article-title":"Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019 (COVID-19)","volume":"76","author":"Hogan","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.lfs.2026.124357_bb0155","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","article-title":"Accelerating antiviral drug discovery: lessons from COVID-19","volume":"22","author":"von Delft","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0160","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1073\/pnas.0910108106","article-title":"Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein","volume":"107","author":"Roymans","year":"2010","journal-title":"P Natl Acad Sci USA."},{"issue":"13","key":"10.1016\/j.lfs.2026.124357_bb0165","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of Ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.lfs.2026.124357_bb0170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12250-014-3530-y","article-title":"Coronavirus MHV-A59 infects the lung and causes severe pneumonia in C57BL\/6 mice","volume":"29","author":"Yang","year":"2014","journal-title":"Virol. Sin."},{"key":"10.1016\/j.lfs.2026.124357_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2018.08.022","article-title":"Characterizing replication kinetics and plaque production of type I feline infectious peritonitis virus in three feline cell lines","volume":"525","author":"O\u2019Brien","year":"2018","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.lfs.2026.124357_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156552","article-title":"HTCC: broad range inhibitor of coronavirus entry","volume":"11","author":"Milewska","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2026.124357_bb0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virol.2021.09.009","article-title":"Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses","volume":"564","author":"Wang","year":"2021","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.lfs.2026.124357_bb0190","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpointS12","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0195","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-020-00325-1","article-title":"Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2026.124357_bb0200","article-title":"Production of Pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting","volume":"145","author":"Millet","year":"2019","journal-title":"J. Vis. Exp."},{"issue":"3","key":"10.1016\/j.lfs.2026.124357_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248348","article-title":"Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2","volume":"16","author":"Neerukonda","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2026.124357_bb0210","series-title":"Impact, Schr\u00f6dinger, LLC, New York, NY","article-title":"Schr\u00f6dinger Release 2020\u20131: Protein Preparation Wizard. Epik, Schr\u00f6dinger, LLC; New York, NY: 2020","author":"Schr\u00f6dinger","year":"2020"},{"key":"10.1016\/j.lfs.2026.124357_bb0215","series-title":"Schr\u00f6dinger Release 2022\u20131: LigPrep","author":"Schr\u00f6dinger","year":"2022"},{"issue":"21","key":"10.1016\/j.lfs.2026.124357_bb0220","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2026.124357_bb0225","series-title":"Schr\u00f6dinger Release 2024\u20132: Glide","author":"Schr\u00f6dinger","year":"2024"},{"issue":"5","key":"10.1016\/j.lfs.2026.124357_bb0230","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03331-22","article-title":"Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2","volume":"10","author":"Wagoner","year":"2022","journal-title":"Microbiol. Spectrum"},{"issue":"3","key":"10.1016\/j.lfs.2026.124357_bb0235","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.lfs.2026.124357_bb0240","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3389\/fimmu.2019.00531","article-title":"Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy","volume":"10","author":"Pizzorno","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124357_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.628144","article-title":"Drug repurposing strategy (DRS): emerging approach to identify potential therapeutics for treatment of novel coronavirus infection","volume":"8","author":"Sahoo","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.lfs.2026.124357_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126959","article-title":"Antiviral Activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a non-human primate model","volume":"10","author":"Ispas","year":"2015","journal-title":"Plos One"},{"issue":"12","key":"10.1016\/j.lfs.2026.124357_bb0255","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2313551","article-title":"Ziresovir in hospitalized infants with respiratory syncytial virus infection","volume":"391","author":"Zhao","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lfs.2026.124357_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00335-4","article-title":"Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines","volume":"4","author":"Zhang","year":"2023","journal-title":"Lancet Microbe."},{"issue":"9","key":"10.1016\/j.lfs.2026.124357_bb0265","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.lfs.2026.124357_bb0270","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.lfs.2026.124357_bb0275","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01485-22","article-title":"A retinol derivative inhibits SARS-CoV-2 infection by interrupting spike-mediated cellular entry","volume":"13","author":"Tong","year":"2022","journal-title":"Mbio"},{"issue":"24","key":"10.1016\/j.lfs.2026.124357_bb0280","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01245-22","article-title":"Sertraline is an effective SARS-CoV-2 entry inhibitor targeting the spike protein","volume":"96","author":"Chen","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2026.124357_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173836","article-title":"Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: insights from atomistic simulations","volume":"894","author":"Padhi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.lfs.2026.124357_bb0290","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1021\/acsinfecdis.2c00006","article-title":"A highly potent SARS-CoV-2 blocking lectin protein","volume":"8","author":"Ahan","year":"2022","journal-title":"Acs Infect Dis."},{"key":"10.1016\/j.lfs.2026.124357_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114426","article-title":"Identification, optimization, and biological evaluation of 3-O-\u03b2-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein","volume":"238","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0300","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03238-21","article-title":"Targeting the fusion process of SARS-CoV-2 infection by small molecule inhibitors","volume":"13","author":"Park","year":"2022","journal-title":"Mbio"},{"issue":"7909","key":"10.1016\/j.lfs.2026.124357_bb0305","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41586-022-04661-w","article-title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic","volume":"605","author":"Shapira","year":"2022","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.lfs.2026.124357_bb0310","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1128\/JVI.02433-13","article-title":"Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus","volume":"87","author":"Gao","year":"2013","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.lfs.2026.124357_bb0315","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1016\/j.apsb.2025.06.029","article-title":"Yeast-two-hybrid based high-throughput screening to discover SARS-CoV-2 fusion inhibitors by targeting the HR1\/HR2 interaction","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.lfs.2026.124357_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/v15040944","article-title":"Evolution of SARS-CoV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies","volume":"15","author":"Zabidi","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0325","doi-asserted-by":"crossref","first-page":"2297553","DOI":"10.1080\/22221751.2023.2297553","article-title":"The impact of S2 mutations on omicron SARS-CoV-2 cell surface expression and fusogenicity","volume":"13","author":"Escalera","year":"2024","journal-title":"Emerg Microbes Infect."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0330","article-title":"A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics","volume":"15","author":"Chatterjee","year":"2023","journal-title":"Immunological Landscape, Immune Escape, and Therapies. Viruses."},{"issue":"10","key":"10.1016\/j.lfs.2026.124357_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25105188","article-title":"Pseudovirus-based Systems for Screening Natural Antiviral Agents: a comprehensive review","volume":"25","author":"Trischitta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2026.124357_bb0340","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019Kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.lfs.2026.124357_bb0345","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0350","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrmicro1326","article-title":"Virus membrane-fusion proteins: more than one way to make a hairpin","volume":"4","author":"Kielian","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.lfs.2026.124357_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0360","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41467-024-45480-z","article-title":"A general computational design strategy for stabilizing viral class I fusion proteins","volume":"15","author":"Gonzalez","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.lfs.2026.124357_bb0365","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.bmcl.2014.11.018","article-title":"The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1","volume":"25","author":"Bond","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0370","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41467-017-00170-x","article-title":"Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor","volume":"8","author":"Roymans","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.lfs.2026.124357_bb0375","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.lfs.2026.124357_bb0380","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.lfs.2026.124357_bb0385","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.00976-10","article-title":"Combinatorial approaches to the prevention and treatment of HIV-1 infection","volume":"55","author":"Pirrone","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.lfs.2026.124357_bb0390","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: from discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.lfs.2026.124357_bb0395","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","article-title":"Drug combination therapy for emerging viral diseases","volume":"26","author":"Shyr","year":"2021","journal-title":"Drug Discov. Today"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526001669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526001669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:10:49Z","timestamp":1778944249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526001669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":79,"alternative-id":["S0024320526001669"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124357","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124357"}}